These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

125 related items for PubMed ID: 24589908

  • 1. The c.480C>G polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemia.
    Di Paolo A, Polillo M, Capecchi M, Cervetti G, Baratè C, Angelini S, Guerrini F, Fontanelli G, Arici R, Ciabatti E, Grassi S, Bocci G, Hrelia P, Danesi R, Petrini M, Galimberti S.
    Pharmacogenomics J; 2014 Aug; 14(4):328-35. PubMed ID: 24589908
    [Abstract] [Full Text] [Related]

  • 2. SLC22A1-ABCB1 haplotype profiles predict imatinib pharmacokinetics in Asian patients with chronic myeloid leukemia.
    Singh O, Chan JY, Lin K, Heng CC, Chowbay B.
    PLoS One; 2012 Aug; 7(12):e51771. PubMed ID: 23272163
    [Abstract] [Full Text] [Related]

  • 3. Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia.
    Yamakawa Y, Hamada A, Nakashima R, Yuki M, Hirayama C, Kawaguchi T, Saito H.
    Ther Drug Monit; 2011 Apr; 33(2):244-50. PubMed ID: 21311410
    [Abstract] [Full Text] [Related]

  • 4. The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia.
    Giannoudis A, Wang L, Jorgensen AL, Xinarianos G, Davies A, Pushpakom S, Liloglou T, Zhang JE, Austin G, Holyoake TL, Foroni L, Kottaridis PD, Müller MC, Pirmohamed M, Clark RE.
    Blood; 2013 Jan 24; 121(4):628-37. PubMed ID: 23223357
    [Abstract] [Full Text] [Related]

  • 5. Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype.
    Gurney H, Wong M, Balleine RL, Rivory LP, McLachlan AJ, Hoskins JM, Wilcken N, Clarke CL, Mann GJ, Collins M, Delforce SE, Lynch K, Schran H.
    Clin Pharmacol Ther; 2007 Jul 24; 82(1):33-40. PubMed ID: 17495881
    [Abstract] [Full Text] [Related]

  • 6. Association of genotypes and haplotypes of multi-drug transporter genes ABCB1 and ABCG2 with clinical response to imatinib mesylate in chronic myeloid leukemia patients.
    Au A, Aziz Baba A, Goh AS, Wahid Fadilah SA, Teh A, Rosline H, Ankathil R.
    Biomed Pharmacother; 2014 Apr 24; 68(3):343-9. PubMed ID: 24581936
    [Abstract] [Full Text] [Related]

  • 7. [Study on imatinib trough concentration, efficacy and their relation in chronic myelocytic leukemia].
    Zhong JS, Meng FY, Xu D, Zhou HS, Dai M.
    Zhonghua Xue Ye Xue Za Zhi; 2012 Mar 24; 33(3):177-82. PubMed ID: 22781602
    [Abstract] [Full Text] [Related]

  • 8. OCT1 genetic variants are associated with long term outcomes in imatinib treated chronic myeloid leukemia patients.
    Koren-Michowitz M, Buzaglo Z, Ribakovsky E, Schwarz M, Pessach I, Shimoni A, Beider K, Amariglio N, le Coutre P, Nagler A.
    Eur J Haematol; 2014 Apr 24; 92(4):283-8. PubMed ID: 24215657
    [Abstract] [Full Text] [Related]

  • 9. [Effects of hOCT1 and ABCB1 gene on the efficacy of imatinib mesylate in chronic myelocytic leukemia].
    Chen WW, Meng FY, Zhong JS, Yin CX, Wang ZX.
    Zhonghua Yi Xue Za Zhi; 2012 May 29; 92(20):1405-8. PubMed ID: 22883199
    [Abstract] [Full Text] [Related]

  • 10. Population pharmacokinetics of imatinib in Iranian patients with chronic-phase chronic myeloid leukemia.
    Golabchifar AA, Rezaee S, Ghavamzadeh A, Alimoghaddam K, Dinan NM, Rouini MR.
    Cancer Chemother Pharmacol; 2014 Jul 29; 74(1):85-93. PubMed ID: 24817601
    [Abstract] [Full Text] [Related]

  • 11. [Influence of hOCT1 polymorphism on imatinib mesylate effectiveness in chronic myelogenous leukemia patients].
    Hu N, Zhu HL, Liu HW, Zeng CX, Meng WT, Liu T.
    Zhonghua Xue Ye Xue Za Zhi; 2009 Sep 29; 30(9):596-600. PubMed ID: 19954617
    [Abstract] [Full Text] [Related]

  • 12. Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia.
    Giannoudis A, Davies A, Lucas CM, Harris RJ, Pirmohamed M, Clark RE.
    Blood; 2008 Oct 15; 112(8):3348-54. PubMed ID: 18669873
    [Abstract] [Full Text] [Related]

  • 13. Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients.
    Seong SJ, Lim M, Sohn SK, Moon JH, Oh SJ, Kim BS, Ryoo HM, Chung JS, Joo YD, Bang SM, Jung CW, Kim DH, Park SY, Yoon SS, Kim I, Lee HG, Won JH, Min YH, Cheong JW, Park JS, Eom KS, Hyun MS, Kim MK, Kim H, Park MR, Park J, Kim CS, Kim HJ, Kim YK, Park EK, Zang DY, Jo DY, Lee HW, Yoon YR.
    Ann Oncol; 2013 Mar 15; 24(3):756-60. PubMed ID: 23117072
    [Abstract] [Full Text] [Related]

  • 14. Can "specific" OCT1 inhibitors be used to determine OCT1 transporter activity toward imatinib?
    Burger H, Mathijssen RH, Sparreboom A, Wiemer EA.
    Blood; 2013 Jun 13; 121(24):4965-6. PubMed ID: 23766461
    [No Abstract] [Full Text] [Related]

  • 15. Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy.
    Angelini S, Soverini S, Ravegnini G, Barnett M, Turrini E, Thornquist M, Pane F, Hughes TP, White DL, Radich J, Kim DW, Saglio G, Cilloni D, Iacobucci I, Perini G, Woodman R, Cantelli-Forti G, Baccarani M, Hrelia P, Martinelli G.
    Haematologica; 2013 Feb 13; 98(2):193-200. PubMed ID: 22875622
    [Abstract] [Full Text] [Related]

  • 16. [H-oCT1 gene expression as a predictor of major and complete molecular response to imatinib of chronic myeloid leukemia. Single center experience].
    Sacha T, Czekalska S, Foryciarz K, Zawada M, Florek I, Cwynar D, Wator G, Balwierz W, Skotnicki AB.
    Przegl Lek; 2011 Feb 13; 68(4):191-5. PubMed ID: 21853672
    [Abstract] [Full Text] [Related]

  • 17. Polymorphisms in the human organic cation transporter and the multidrug resistance gene: correlation with imatinib levels and clinical course in patients with chronic myeloid leukemia.
    Vine J, Cohen SB, Ruchlemer R, Goldschmidt N, Levin M, Libster D, Gural A, Gatt ME, Lavie D, Ben-Yehuda D, Rund D.
    Leuk Lymphoma; 2014 Nov 13; 55(11):2525-31. PubMed ID: 24524306
    [Abstract] [Full Text] [Related]

  • 18. Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia.
    Clark RE, Davies A, Pirmohamed M, Giannoudis A.
    Leuk Lymphoma; 2008 Apr 13; 49(4):639-42. PubMed ID: 18398725
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.